VEGFA and neoplasm: Despite encouraging outcomes observed in preclinical studies, anti-VEGF monotherapies like bevacizumab, sunitinib, and aflibercept have demonstrated benefits in specific tumor types such as advanced-stage renal cell carcinoma, hepatocellular carcinoma, and colorectal carcinoma.